Peringatan Keamanan

Cytarabine syndrome may develop - it is characterized by fever, myalgia, bone pain, occasionally chest pain, maculopapular rash, conjunctivitis, and malaise.

Cytarabine

DB00987

small molecule approved investigational

Deskripsi

A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Struktur Molekul 2D

Berat 243.2166
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 10 minutes
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Less than 20% of the orally administered dose is absorbed from the gastrointestinal tract.

Metabolisme

Hepatic.

Rute Eliminasi

The primary route of elimination of cytarabine is metabolism to the inactive compound ara-U, followed by urinary excretion of ara-U.

Interaksi Obat

592 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Cytarabine.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cytarabine.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Cytarabine.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Cytarabine.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Cytarabine.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Cytarabine.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Cytarabine.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cytarabine.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cytarabine.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cytarabine.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cytarabine.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Cytarabine.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Cytarabine.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Cytarabine.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cytarabine.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Cytarabine.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cytarabine.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Cytarabine.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Cytarabine.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cytarabine.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cytarabine.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Cytarabine.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cytarabine.
Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Cytarabine.
Cladribine Cytarabine may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Cytarabine.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Cytarabine.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Cytarabine.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Cytarabine.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Cytarabine.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Cytarabine.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Cytarabine.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Cytarabine.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Cytarabine.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Cytarabine.
Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Cytarabine.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cytarabine.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Cytarabine.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Cytarabine.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Cytarabine.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Cytarabine.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Cytarabine.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Cytarabine.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Cytarabine.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Cytarabine.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Cytarabine.
Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Cytarabine.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Cytarabine.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Cytarabine.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Cytarabine.
Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Cytarabine.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Cytarabine.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Cytarabine.
Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Cytarabine.
Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Cytarabine.
Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Cytarabine.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Cytarabine.
Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Cytarabine.
Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Cytarabine.
Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Cytarabine.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Cytarabine.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Cytarabine.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Cytarabine.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Cytarabine.
Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Cytarabine.
Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Cytarabine.
Azathioprine The risk or severity of adverse effects can be increased when Cytarabine is combined with Azathioprine.
Hydroxyurea The risk or severity of adverse effects can be increased when Cytarabine is combined with Hydroxyurea.
Mycophenolic acid The risk or severity of adverse effects can be increased when Cytarabine is combined with Mycophenolic acid.
Mercaptopurine The risk or severity of adverse effects can be increased when Cytarabine is combined with Mercaptopurine.
Thalidomide The risk or severity of adverse effects can be increased when Cytarabine is combined with Thalidomide.
Melphalan The risk or severity of adverse effects can be increased when Cytarabine is combined with Melphalan.
Fludarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Fludarabine.
Capecitabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Capecitabine.
Trilostane The risk or severity of adverse effects can be increased when Cytarabine is combined with Trilostane.
Procarbazine The risk or severity of adverse effects can be increased when Cytarabine is combined with Procarbazine.
Arsenic trioxide The risk or severity of adverse effects can be increased when Cytarabine is combined with Arsenic trioxide.
Idarubicin The risk or severity of adverse effects can be increased when Cytarabine is combined with Idarubicin.
Estramustine The risk or severity of adverse effects can be increased when Cytarabine is combined with Estramustine.
Lomustine The risk or severity of adverse effects can be increased when Cytarabine is combined with Lomustine.
Eculizumab The risk or severity of adverse effects can be increased when Cytarabine is combined with Eculizumab.
Decitabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Decitabine.
Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Cytarabine.
Ciclesonide The risk or severity of adverse effects can be increased when Cytarabine is combined with Ciclesonide.
Stepronin The risk or severity of adverse effects can be increased when Cytarabine is combined with Stepronin.
Hydroxychloroquine The risk or severity of adverse effects can be increased when Cytarabine is combined with Hydroxychloroquine.
Castanospermine The risk or severity of adverse effects can be increased when Cytarabine is combined with Castanospermine.
Vorinostat The risk or severity of adverse effects can be increased when Cytarabine is combined with Vorinostat.
2-Methoxyethanol The risk or severity of adverse effects can be increased when Cytarabine is combined with 2-Methoxyethanol.
Brequinar The risk or severity of adverse effects can be increased when Cytarabine is combined with Brequinar.
Thiotepa The risk or severity of adverse effects can be increased when Cytarabine is combined with Thiotepa.
Aldosterone The risk or severity of adverse effects can be increased when Cytarabine is combined with Aldosterone.
Pirfenidone The risk or severity of adverse effects can be increased when Cytarabine is combined with Pirfenidone.
Belinostat The risk or severity of adverse effects can be increased when Cytarabine is combined with Belinostat.
Trabectedin The risk or severity of adverse effects can be increased when Cytarabine is combined with Trabectedin.
Interferon alfa The risk or severity of adverse effects can be increased when Cytarabine is combined with Interferon alfa.
Glatiramer The risk or severity of adverse effects can be increased when Cytarabine is combined with Glatiramer.
Briakinumab The risk or severity of adverse effects can be increased when Cytarabine is combined with Briakinumab.
Human interferon omega-1 The risk or severity of adverse effects can be increased when Cytarabine is combined with Human interferon omega-1.
Panobinostat The risk or severity of adverse effects can be increased when Cytarabine is combined with Panobinostat.

Target Protein

DNA polymerase beta POLB
DNA polymerase catalytic subunit
DNA

Referensi & Sumber

Synthesis reference: Michael Kluge, Herbert Schott, "Cytarabine derivatives, the preparation and use thereof." U.S. Patent US5641758, issued August, 1992.

Contoh Produk & Brand

Produk: 57 • International brands: 2
Produk
  • Aj-cytarabine
    Solution • 100 mg / mL • Intrathecal; Intravenous; Subcutaneous • Canada • Generic • Approved
  • Cytarabine
    Injection, powder, lyophilized, for solution • 100 mg/5mL • Intrathecal; Intravenous; Subcutaneous • US • Generic • Approved
  • Cytarabine
    Injection, powder, lyophilized, for solution • 500 mg/10mL • Intrathecal; Intravenous; Subcutaneous • US • Generic • Approved
  • Cytarabine
    Injection, powder, lyophilized, for solution • 1 g/10mL • Intrathecal; Intravenous; Subcutaneous • US • Generic • Approved
  • Cytarabine
    Injection, powder, lyophilized, for solution • 2 g/20mL • Intrathecal; Intravenous; Subcutaneous • US • Generic • Approved
  • Cytarabine
    Injection, powder, lyophilized, for solution • 100 mg/5mL • Intrathecal; Intravenous; Subcutaneous • US • Generic • Approved
  • Cytarabine
    Injection, powder, lyophilized, for solution • 500 mg/10mL • Intrathecal; Intravenous; Subcutaneous • US • Generic • Approved
  • Cytarabine
    Injection, powder, lyophilized, for solution • 1 g/10mL • Intrathecal; Intravenous; Subcutaneous • US • Generic • Approved
Menampilkan 8 dari 57 produk.
International Brands
  • Ara-C — Gobbi
  • Cytosar-U — Pfizer

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul